Millions of adults live with major depressive disorder (MDD), which has a negative impact on their physical and emotional well-being.
New data presented at this year’s AMCP Nexus and Psych Congress meetings add to the growing body of evidence showing the significant financial burden associated with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation.
Highlights from two separate studies include:
“Incremental Health Care Costs for Persons with Treatment-Resistant Depression in Managed Care Organizations,” a retrospective cohort study used data from the electronic medical records (EMR) and administrative systems of the Kaiser Permanente Northwest (KPNW), included KPNW adult members. The medical and mental healthcare costs of people with TRD were compared to those with MDD and non-MDD controls. The analysis also looked at whether inclusion of clinical symptoms from the nine-item Patient Health Questionnaire (PHQ-9) can refine the understanding of healthcare costs for people with TRD. Groups were evaluated on healthcare costs using generalized linear modeling.
Findings show the association between the magnitude of depression symptom burden and costs, underscoring the importance of appropriate management of depression symptoms from an economic perspective:
- Adults with MDD in managed care systems had 82% higher total annual healthcare costs compared to those with no evidence of depression. Those with TRD had 164% higher costs compared to those with no evidence of depression.
- Among patients with depression, whether MDD or TRD, as symptom burden increased, costs increased as well.
- Data from the EMR and administrative systems of KPNW were used to analyze the healthcare costs of these three populations.
- Comparing the cost difference between TRD and MDD patients directly, costs were 45% higher among those with TRD.